浙江本輪疫情累計報告確診病例37例 無症狀感染者41例
格隆匯12月10日丨據央視,從浙江省新冠肺炎疫情防控第84場新聞發佈會上獲悉,自12月5日以來,截至12月10日下午3時,本輪疫情浙江省寧波、紹興和杭州三地累計報告確診病例37例(均爲輕型)、無症狀感染者41例。其中,寧波累計報告確診病例18例、無症狀感染者12例;紹興累計報告確診病例16例、無症狀感染者20例;杭州累計報告確診病例3例、無症狀感染者9例。全省已累計排查密接者2921人,次密接者13950人,均已落實管控措施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.